Jason Karlawish, MD with experts in cognitive aging research from six different countries addresses “Ethical challenges in preclinical Alzheimer’s disease observational studies and trials: Results of the Barcelona Summit“ in the current issue of Alzheimer’s & Dementia, the journal of the Alzheimer’s Association.
“To review and discuss the novel ethical challenges that need to be overcome for successful performance of trials in the preclinical stage of AD, a multi-stakeholder group met in a 1-day summit entitled “Ethical challenges of future Alzheimer’s disease clinical research” held in Barcelona in October 2014. This reunion was organized by the Barcelonaβeta Brain Research Center, the research institute where the Pasqual Maragall Foundation conducts all its scientific activities devoted to clinical research for the prevention of AD. This discussion group included experts from academia, including AD researchers and bioethicists, patients’ organizations and regulatory agencies. This article summarizes the outcome of that meeting, where these ethical and policy challenges were debated and recommendations to address them throughout the research process were proposed, discussed, and agreed”
Dr. Karlawish is a UPenn PRC Principal Investigator and leads the UPenn Healthy Brain Research Network.
